Myelosuppression Clinical Trial
Official title:
Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy
Myelosuppression (bone marrow suppression) is the most important toxic side effect of the
majority of chemotherapeutic agents and typically is the dose limiting factor. Death
occurring after chemotherapy usually results either from infection related to drug induced
leucopenia or from bleeding related to thrombocytopenia. Colony stimulating factors (CSFs)
are widely used in the treatment of chemotherapy induced neutropenia. The same
Erythropoetines are used in the treatment of chemotherapy induced anemia. Both treatments
are expensive and have several side effects.
In our previous stud (1) we found a special kind of honey: Life-Mel Honey to reduce the
incidence of chemotherapy induced pancytopenia and improving quality of life.
The aim of the recent planed study is to provide prophylactic and protective treatment
against neutropenia reducing the need for secondary CSF administration in patients receiving
chemotherapy along with a natural and non expensive honey: Profonycia.
This honey which is expressed in Kibutz Shamir in Upper Galliee seems promising and easy for
administration: given 5 gr/day per os for 7 days from the administration of chemotherapy.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00151866 -
Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma
|
Phase 3 | |
| Recruiting |
NCT03126890 -
Investigation of the Correlation Between Plasma Concentration of Linezolid Antibiotic and Treatment Response and Adverse Reactions
|
||
| Completed |
NCT02692742 -
Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
|
Phase 2 | |
| Completed |
NCT05442177 -
Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity
|
||
| Terminated |
NCT02375334 -
Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy
|
||
| Not yet recruiting |
NCT03846414 -
Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
|
||
| Recruiting |
NCT04905329 -
A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
|
||
| Not yet recruiting |
NCT05780294 -
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
|
Phase 3 |